ClinicalTrials.gov
public full text
Public Domain
Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile
Open label, single dose and phase I study. The primary objective: To determine the maximum tolerated dose in Single dose The secondary objective: to evaluate the toxicity in administration to determine desirable dosing amount for phase II to evaluate tumor response in progressive solid cancer patients to evaluate pharmacokinetic/ pharmacodynamic profile.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors#850016
- Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors#877703
- A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy#917352
- Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects#870994
- A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors#1010581
Record · ID 1151004
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive